Cargando…

Safety and Tolerability of Six Months of Isoniazid Plus Pyridoxine or Three Months of Rifampicin for Tuberculosis among Subjects with Diabetes Mellitus: A Randomized Trial

Tuberculosis (TB) associated with diabetes mellitus (DM) is a growing problem, particularly in low- and medium-resource countries. We conducted an open-label, parallel-group, randomized, and controlled trial in a tertiary care center in Mexico City to assess TB preventive treatment (TPT) with isonia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamez-Torres, Karla M., Mongua-Rodríguez, Norma, Ferreyra-Reyes, Leticia, Torres-Gonzalez, Pedro, Delgado-Sánchez, Guadalupe, Martínez-Hernández, Maribel, Bobadilla-del-Valle, Miriam, Jasso-Sosa, Velma Y., López-Castillo, Priscila del S., Ferreira-Guerrero, Elizabeth, Cruz-Hervert, Luis Pablo, Sifuentes-Osornio, Jose, Aguilar-Salinas, Carlos A., García-García, Lourdes, Ponce-de-Leon, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459081/ https://www.ncbi.nlm.nih.gov/pubmed/37630477 http://dx.doi.org/10.3390/microorganisms11081917

Ejemplares similares

Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis
por: Torres, Martha, et al.
Publicado: (2015)

Isoniazid Mono-Resistant Tuberculosis: Impact on Treatment Outcome and Survival of Pulmonary Tuberculosis Patients in Southern Mexico 1995-2010
por: Báez-Saldaña, Renata, et al.
Publicado: (2016)

Molecular clustering of patients with diabetes and pulmonary tuberculosis: A systematic review and meta-analysis
por: Blanco-Guillot, Francles, et al.
Publicado: (2017)

Oral pyridoxine can substitute for intravenous pyridoxine in managing patients with severe poisoning with isoniazid and rifampicin fixed dose combination tablets: a case report
por: Dilrukshi, M. D. S. A., et al.
Publicado: (2017)

Genotyping and spatial analysis of pulmonary tuberculosis and diabetes cases in the state of Veracruz, Mexico
por: Blanco-Guillot, Francles, et al.
Publicado: (2018)

Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes
por: Jiménez-Corona, María Eugenia, et al.
Publicado: (2013)

Fatal poisoning by isoniazid and rifampicin
por: Sridhar, A., et al.
Publicado: (2012)

Isoniazid- and rifampicin-induced thrombocytopenia
por: Yakar, Fatih, et al.
Publicado: (2013)

3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review
por: Assefa, Yibeltal, et al.
Publicado: (2018)

Results of the Implementation of a Pilot Model for the Bidirectional Screening and Joint Management of Patients with Pulmonary Tuberculosis and Diabetes Mellitus in Mexico
por: Castellanos-Joya, Martín, et al.
Publicado: (2014)

Human tuberculosis caused by Mycobacterium bovis: a retrospective comparison with Mycobacterium tuberculosis in a Mexican tertiary care centre, 2000–2015
por: Torres-Gonzalez, Pedro, et al.
Publicado: (2016)

Expression of USP18 and IL2RA Is Increased in Individuals Receiving Latent Tuberculosis Treatment with Isoniazid
por: de Oyarzabal, Eleane, et al.
Publicado: (2019)

Mycobacterium tuberculosis lineage 4 associated with cavitations and treatment failure
por: Ordaz-Vázquez, Anabel, et al.
Publicado: (2023)

Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine
por: McClintock, Adelaide H., et al.
Publicado: (2017)

Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
por: Lai, Wendy A., et al.
Publicado: (2022)

Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin
por: Ramachandran, Geetha, et al.
Publicado: (2012)

Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children
por: Mukherjee, Aparna, et al.
Publicado: (2015)

Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients
por: Kumar, A. K. Hemanth, et al.
Publicado: (2018)

Clofazimine, but Not Isoniazid or Rifampicin, Augments Platelet Activation in vitro
por: Anderson, Ronald, et al.
Publicado: (2018)

Mycobacterium tuberculosis complex bacteremia among HIV and non-HIV patients in a Mexican tertiary care center
por: Tamez-Torres, Karla Maria, et al.
Publicado: (2018)

Protective Effects of Metallothionein on Isoniazid and Rifampicin-Induced Hepatotoxicity in Mice
por: Lian, Yong, et al.
Publicado: (2013)

Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
por: Aruldhas, Blessed Winston, et al.
Publicado: (2019)

Factors Associated to Prevalence and Incidence of Carbapenem-Resistant Enterobacteriaceae Fecal Carriage: A Cohort Study in a Mexican Tertiary Care Hospital
por: Torres-Gonzalez, Pedro, et al.
Publicado: (2015)

Prevalence of Latent and Active Tuberculosis among Dairy Farm Workers Exposed to Cattle Infected by Mycobacterium bovis
por: Torres-Gonzalez, Pedro, et al.
Publicado: (2013)

A Novel Scoring System to Measure Radiographic Abnormalities and Related Spirometric Values in Cured Pulmonary Tuberculosis
por: Báez-Saldaña, Renata, et al.
Publicado: (2013)

Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co–therapy
por: Li, Feng, et al.
Publicado: (2013)

Effectiveness of ellagic acid on isoniazid-rifampicin induced liver damage in rats
por: Ambrose, Samuel Stephen, et al.
Publicado: (2013)

Hepatoprotective Activity of Heptoplus on Isoniazid and Rifampicin Induced Liver Damage in Rats
por: Sankar, M., et al.
Publicado: (2015)

Naringenin protects against isoniazid- and rifampicin-induced apoptosis in hepatic injury
por: Wang, Chao, et al.
Publicado: (2016)

Simultaneous Spectrophotometric Determination of Rifampicin, Isoniazid and Pyrazinamide in a Single Step
por: Asadpour-Zeynali, Karim, et al.
Publicado: (2016)

Toxicoproteomic Profiling of hPXR Transgenic Mice Treated with Rifampicin and Isoniazid
por: Brewer, Christopher Trent, et al.
Publicado: (2020)

Association between Highly Active Antiretroviral Therapy and Type of Infectious Respiratory Disease and All-Cause In-Hospital Mortality in Patients with HIV/AIDS: A Case Series
por: Báez-Saldaña, Renata, et al.
Publicado: (2015)

Cost‐effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda
por: Ferguson, Olivia, et al.
Publicado: (2020)

Development of Pseudomembranous Colitis Four Months after Initiation of Rifampicin
por: Choi, Jeong Moon, et al.
Publicado: (2011)

Four months of rifampicin monotherapy for latent tuberculosis infection in children
por: Oh, Chi Eun, et al.
Publicado: (2021)

The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance
por: Van Deun, Armand, et al.
Publicado: (2020)

Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting
por: Pease, Christopher, et al.
Publicado: (2021)

Seroprevalence of Poliomyelitis Antibodies Among Children Aged 1 to 4 Years Old and Factors Associated With Poliovirus Susceptibility; Mexican Health and Nutrition Survey, 2012
por: Díaz-Quiñónez, José Alberto, et al.
Publicado: (2018)

Potential Effect of Statins on Mycobacterium tuberculosis Infection
por: Guerra-De-Blas, Paola Del Carmen, et al.
Publicado: (2018)

Isoniazid, Pyrazinamide and Rifampicin Content Variation in Split Fixed-Dose Combination Tablets
por: Pouplin, Thomas, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rn11klivb8c35qdu554ife5mfh